Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $8,853,641 | $8,644,485 | $7,948,313 |
| - Cash | $539,092 | $494,046 | $517,923 | $559,543 |
| + Debt | $331,369 | $792,534 | $847,272 | $856,616 |
| Enterprise Value | – | $9,152,129 | $8,973,834 | $8,245,386 |
| Revenue | $213,634 | $158,045 | $100,954 | $173,916 |
| % Growth | 35.2% | 56.6% | -42% | – |
| Gross Profit | $191,280 | $126,598 | $83,437 | $159,893 |
| % Margin | 89.5% | 80.1% | 82.6% | 91.9% |
| EBITDA | -$53,353 | $2,319 | -$44,234 | -$37,893 |
| % Margin | -25% | 1.5% | -43.8% | -21.8% |
| Net Income | -$60,989 | -$38,855 | -$94,626 | -$38,469 |
| % Margin | -28.5% | -24.6% | -93.7% | -22.1% |
| EPS Diluted | -1 | -0.82 | -1.58 | -0.64 |
| % Growth | -22% | 48.1% | -146.9% | – |
| Operating Cash Flow | $2,153 | -$7,341 | -$14,313 | -$87,176 |
| Capital Expenditures | -$53 | -$4,338 | -$703 | -$383 |
| Free Cash Flow | $2,100 | -$11,679 | -$15,016 | -$87,559 |